We're back and knee-deep in BIO2014 follow up work. Lacerta Bio was joined by 15,665 other "industry leaders" in days full of partnering discussions, pen-grabbing, eating and drinking, and…
An excellent analysis of the AstraZeneca pipeline performance was recently published in Nature Review. The objective of this study was to identify and assess key factors which drive R&D performance:…
This morning, Thompson Reuters and BIO presented a good webinar on preparing for BIO. I think it will be re-broadcast tomorrow. A lot of time was spent on characterising transactions…
Our friends at Pharmaphorum posted an overview of the recent WHO guidance for the treatment of hepatitis C. Of note, These new oral drugs are able to cure…
Much ink has already been spilled discussing the acquisition of Ranbaxy from Daiichi by Sun Pharma in an all stock transaction. A good analysis by a former Ranbaxy executive…
Yesterday, MannKind Corporation annouced that the FDA voted 13-1 in favor of an approval for Afrezza. You can find the press release here. We've Seen This Movie Before For…
This week, the financial press is going bonkers over the acquisition of WhatsApp by Facebook for $19 billion in cash, stock, and Facebook tchotkes. We're not experts in this space,…
Are we the only ones shocked by this? Despite efforts by the Obama administration to ease shortages of critical drugs, shortfalls have persisted, forcing doctors to resort to rationing…
We're still knee-deep in our follow up activities from the San Francisco conferences and receptions. Specifically, we spent the bulk of our time at the rapidly-growing Biotech Showcase…
Yesterday the Wall Street Journal summarized the current situation in antibiotic drug development and commercialization. To summarize: Big Pharma is slowly returning to antibiotic (really, antibacterial) drug discovery…